Saturday 17 October 2026
Export LAB’s income statement to Excel — free account
Standard BioTools Inc.
LAB Healthcare Medical Devices
In the quarter to June 2026, revenue fell 7.62%, EPS grew 22.2%, free cash flow grew 52.8% and total debt was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.63
0.03
−4.55%
Follow LAB
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
2 | 3 | 6 | 4 | 5 | 1 | 3 | 5 | 4 | 4 |
P/S ratio |
2.11 | 2.02 | 3.03 | 1.98 | 3.13 | 2.28 | 1.04 | 1.65 | 6.79 | 5.72 |
Altman Z-Score |
(1.69) | (2.04) | (1.49) | (1.96) | (1.38) | (2.99) | (3.20) | (3.95) | 0.00 | (0.82) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(4.62) | (5.51) | (4.80) | (5.97) | (5.78) | (9.28) | (5.45) | (9.63) | (0.87) | (1.44) |
Beneish M-Score |
(3.50) | (3.02) | (2.95) | (2.66) | (2.77) | (2.94) | (3.56) | (2.94) | (2.23) | (2.93) |
P/Operating CF |
(20.52) | 310.84 | (535.74) | (42.11) | (115.80) | (42.43) | (5.31) | (12.50) | (43.97) | (410.49) |
P/B ratio |
4.14 | 6.64 | 4.74 | 1.51 | 3.11 | 3.14 | 0.00 | 0.00 | 1.31 | 1.15 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 70.34 | 0.00 | 0.00 | 0.00 | 0.00 | 1.87 | 1.72 |
EV/Sales |
3.41 | 3.31 | 3.70 | 1.96 | 3.05 | 2.60 | 0.01 | 0.66 | 3.63 | 3.59 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(9.09) | (14.01) | (16.60) | (6.52) | (27.30) | (7.71) | (0.01) | (1.61) | (2.30) | (4.12) |
EV/FCF |
(6.99) | (10.46) | (13.01) | (5.17) | (12.12) | (5.31) | (0.01) | (1.32) | (2.09) | (3.43) |
Quick Ratio |
2.51 | 2.34 | 2.98 | 2.36 | 1.73 | 0.94 | 4.21 | 1.23 | 4.67 | 1.86 |
Current Ratio |
3.28 | 2.83 | 3.38 | 2.93 | 2.17 | 1.45 | 4.81 | 1.45 | 5.70 | 4.19 |
Net Debt/EBITDA |
(2.47) | (3.35) | (3.30) | 0.09 | 0.35 | (0.83) | 0.99 | 1.69 | 2.48 | 1.84 |
Debt/Assets |
63.63% | 67.94% | 56.66% | 21.02% | 17.61% | 25.82% | 16.63% | 2.78% | 0.05% | 0.05% |
Debt/Equity |
3.66 | 6.31 | 2.39 | 0.36 | 0.41 | 0.75 | 0.28 | 0.06 | 0.00 | 0.00 |
Asset Turnover |
0.31 | 0.34 | 0.38 | 0.41 | 0.47 | 0.44 | 0.29 | 0.30 | 0.19 | 0.14 |
Operating CF/Net income |
0.52 | 0.40 | 0.43 | 0.54 | 0.29 | 0.74 | 0.47 | 0.58 | 0.78 | 0.99 |
Capex/Depreciation |
(0.28) | (0.09) | (0.01) | (0.14) | (0.69) | (0.82) | (0.27) | (0.20) | (0.89) | (1.00) |
Interest Coverage |
(12.58) | (10.02) | (3.47) | (12.11) | (14.29) | (17.65) | (26.83) | (16.77) | (38.45) | (4,240.35) |
| (90.39%) | (143.84%) | (114.53%) | (57.41%) | (36.23%) | (50.71%) | (2,895.83%) | 65.05% | (114.25%) | (16.72%) | |
| (22.47%) | (20.39%) | (19.97%) | (22.79%) | (17.99%) | (19.75%) | (57.13%) | (20.93%) | (39.53%) | (12.69%) | |
ROIC |
(24.23%) | (22.37%) | (20.23%) | (21.51%) | (24.97%) | (30.73%) | (56.35%) | (83.57%) | (44.48%) | (29.07%) |
Return on Tangible Assets |
(90.79%) | (82.22%) | (60.00%) | (90.83%) | (65.50%) | (117.23%) | (99.52%) | (102.16%) | (55.56%) | (20.51%) |
Average Days of Receivables |
51.06 | 53.89 | 53.80 | 59.09 | 67.17 | 51.21 | 64.39 | 67.48 | 59.12 | 57.45 |
Research and Development Expense of Revenue |
36.78% | 30.24% | 26.58% | 26.99% | 26.39% | 29.06% | 38.17% | 24.40% | 31.68% | 30.45% |
Selling, General and Administrative Expense of Revenue |
89.24% | 78.01% | 70.63% | 72.05% | 70.87% | 75.73% | 104.43% | 82.32% | 113.24% | 128.75% |
Intangible Assets out of Total Assets |
0.60 | 0.60 | 0.53 | 0.57 | 0.45 | 0.49 | 0.30 | 0.33 | 0.23 | 0.00 |
Share Based Compensation of Revenue |
13.27% | 8.92% | 9.76% | 9.72% | 10.46% | 12.33% | 15.19% | 12.34% | 34.87% | 34.70% |
Graham Net Nets |
(0.71) | (0.79) | (0.31) | (0.06) | (0.16) | (0.37) | 0.47 | (0.01) | 0.38 | 0.64 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.56 | 6.32 | 0.00 | 0.00 |
Earnings Yield |
(34.52%) | (30.50%) | (17.40%) | (29.02%) | (12.17%) | (19.90%) | (187.69%) | (42.79%) | (31.43%) | (15.63%) |
Free Cash Flow Yield |
(23.11%) | (15.70%) | (9.41%) | (19.08%) | (8.04%) | (21.52%) | (98.03%) | (30.00%) | (25.63%) | (18.27%) |
Revenue per Share |
3.60 | 3.09 | 2.85 | 1.76 | 1.92 | 1.72 | 1.25 | 1.34 | 0.26 | 0.22 |
Operating CF per Share |
(1.35) | (0.73) | (0.64) | (0.53) | (0.21) | (0.58) | (1.14) | (0.55) | (0.41) | (0.19) |
Capex per Share |
(0.17) | (0.05) | (0.01) | (0.04) | (0.18) | (0.17) | (0.05) | (0.04) | (0.02) | (0.02) |
Free Cash Flow per Share |
(1.52) | (0.78) | (0.64) | (0.57) | (0.39) | (0.76) | (1.19) | (0.58) | (0.43) | (0.22) |
Cash per Share |
2.05 | 1.91 | 2.41 | 0.88 | 0.95 | 0.38 | 2.12 | 1.45 | 0.83 | 0.49 |
Shareholders Equity per Share |
1.84 | 0.94 | 1.82 | 2.30 | 1.93 | 1.25 | 2.93 | 2.06 | 1.34 | 1.11 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.84 | 0.94 | 1.82 | 2.30 | 1.93 | 1.25 | 2.93 | 2.06 | 1.34 | 1.11 |
Free Cash Flow |
(44.20) | (25.71) | (25.57) | (37.74) | (28.13) | (57.32) | (93.19) | (46.12) | (151.81) | (82.65) |
Working Capital |
67.17 | 61.33 | 89.52 | 63.28 | 63.41 | 22.50 | 165.37 | 48.89 | 309.99 | 345.96 |
Capital Expenditures |
(5.06) | (1.62) | (0.37) | (2.53) | (12.72) | (13.26) | (3.82) | (2.83) | (8.35) | (8.30) |
Net Current Asset Value |
(156.49) | (161.61) | (104.42) | (15.10) | (68.04) | (108.55) | 48.29 | (1.65) | 235.26 | 310.80 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.05 | 0.02 | 0.00 | 0.02 | 0.09 | 0.10 | 0.04 | 0.03 | 0.09 | 0.10 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
1.10 | 1.54 | 2.83 | 2.19 | 1.05 | 0.58 | 0.56 | 0.58 | 0.41 | 0.43 |
Cash ROIC |
(14.37%) | (8.89%) | (7.53%) | (14.09%) | (10.63%) | (29.53%) | (20.24%) | (16.06%) | (19.85%) | (13.50%) |
Accounts Receivable Turnover |
5.21 | 6.87 | 7.13 | 6.58 | 6.22 | 5.97 | 5.50 | 5.76 | 5.29 | 6.06 |
Accounts Payable Turnover |
9.15 | 12.22 | 12.46 | 11.54 | 7.63 | 6.18 | 6.58 | 6.52 | 6.46 | 8.18 |
Inventory Turnover |
2.42 | 2.84 | 3.65 | 3.94 | 3.27 | 3.02 | 2.88 | 2.66 | 2.23 | 2.10 |
Average Days of Payables |
31.47 | 30.77 | 28.64 | 35.50 | 61.39 | 63.22 | 47.43 | 60.32 | 39.95 | 46.12 |
Days of Inventory on Hand |
159.57 | 110.24 | 92.49 | 95.68 | 131.10 | 124.19 | 128.70 | 134.09 | 164.15 | 170.45 |
Average Receivables |
20.03 | 14.83 | 15.85 | 17.82 | 22.20 | 21.87 | 17.80 | 18.47 | 17.20 | 14.09 |
Average Payables |
5.03 | 4.09 | 4.12 | 4.59 | 7.19 | 9.91 | 9.26 | 8.58 | 7.14 | 5.23 |
Average Inventory |
19.02 | 17.60 | 14.05 | 13.44 | 16.79 | 20.26 | 21.15 | 21.00 | 20.64 | 20.36 |
Average Assets |
338.22 | 296.87 | 295.50 | 284.23 | 294.78 | 299.99 | 332.76 | 356.69 | 467.71 | 590.05 |
Average Common Equity |
84.07 | 42.08 | 51.53 | 112.86 | 146.33 | 116.82 | 6.56 | (114.76) | 161.84 | 448.01 |
Columns are period end dates